Key points are not available for this paper at this time.
Key Points The addition of rituximab to corticosteroid and CsA is safe and effective for first-line treatment of cGVHD. Resistance of PD-L1hi B cells to anti-CD20 depletion may lead to the suppression of activated Tfh cells and cGVHD control.
Malard et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: